Genevant
14 articles about Genevant
-
A Delaware judge on Wednesday agreed with Roivant subsidiary Arbutus and Genevant’s interpretation of specific patent claims regarding the lipid nanoparticle delivery system used by Moderna’s COVID-19 vaccine.
-
Korro Bio and Genevant Sciences Enter into Collaboration Agreement to Develop RNA Editing Therapeutic for Alpha-1 Antitrypsin Deficiency
3/7/2023
Korro Bio and Genevant Sciences today announced that they have entered into an agreement to combine Korro’s powerful RNA editing platform with Genevant’s industry-leading LNP technology to develop a differentiated therapeutic option for patients with Alpha-1 Antitrypsin Deficiency (AATD).
-
Monday, Moderna told a Delaware federal court that it was immune from patent-infringement charges over the COVID-19 vaccine because it supplied the vaccine for a U.S. government effort.
-
Moderna is still fending off patent challenges over the lipid nanoparticle delivery system used in its COVID-19 vaccine.
-
Who is to thank for the COVID vaccine? Many major biopharma companies are asking that question after a series of lawsuits over patent rights to the vaccine and its associated technology.
-
On Monday, Arbutus and Genevant filed a lawsuit against Moderna challenging patent infringement.
-
Arbutus Biopharma and Genevant Sciences File Patent Infringement Lawsuit Against Moderna
2/28/2022
Arbutus Biopharma Corporation and Genevant Sciences today filed a lawsuit in the U.S. District Court for the District of Delaware against Moderna, Inc.
-
Genevant Sciences has announced a collaboration deal with Takeda Pharmaceutical to create and commercialize new therapies to treat two undisclosed types of rare liver diseases.
-
Sarepta Therapeutics and Genevant Sciences Announce Research Collaboration for Lipid Nanoparticle-Based Gene Editing Therapeutics
1/13/2021
-- Alliance will assess the use of Sarepta’s proprietary gene editing technology and Genevant’s proprietary LNP delivery platform for multiple neuromuscular targets -- -- Sarepta to have options for an exclusive license to Genevant’s LNP technology for four neuromuscular indications -- -- Genevant may receive approximately $50 million in near-term payments and is also eligible for significant future milestones and royalties --
-
Genevant Sciences to Present at the Jefferies 2019 Healthcare Conference
6/3/2019
Genevant Sciences announced that Bo Rode Hansen, MBA, PhD, President and Chief Executive Officer, is scheduled to present at the Jefferies 2019 Healthcare Conference in New York City on Friday, June 7, 2019 at 8:00 am EDT.
-
IDBS engaged to help Genevant advance drug discoveries
3/12/2019
The arrangement will combine Genevant’s RNA therapeutic expertise with the R&D and discovery data management expertise of IDBS.
-
BioSpace Movers and Shakers: Jan. 11
1/11/2019
Biopharma companies strengthen the leadership teams during the annual J.P. Morgan Healthcare Conference. -
BioSpace is proud to present its NextGen Bio “Class of 2019,” a list of 20 up-and-coming life science companies in North America that launched* no earlier than 2017.
-
BioSpace Movers and Shakers: Nov. 26
11/26/2018
In a short week leading up to Thanksgiving, several companies made leadership changes as they eye the coming year. We round up who made power moves this past week.